# Cannabinoids & Blood Thinners & Anticoagulants: Evidence, Pharmacokinetics & Safety Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-interactions-blood-thinners-anticoagulants-evidence-4/ > **Published:** 2026-11-02T12:23:07-04:00 | **Last Modified / Clinically Audited:** 2026-11-02T12:23:07-04:00 > **Clinical Summary:** Explore Cannabinoids & Blood Thinners & Anticoagulants: Evidence, Pharmacokinetics... Read clinical evidence and guidance with Dr. Benjamin Caplan at CED C... --- Pharmacology & Safety Series Clinically Audited: November 2026 Table of Contents - [Cannabinoids & Blood Thinners & Anticoagulants: Evidence, Pharmacokinetics & Safety Review](#Cannabinoids_038_Blood_Thinners_038_Anticoagulants_Evidence_Pharmacokinetics_038_Safety_Review)[1. The Primary Pharmacokinetic Mechanism](#1_The_Primary_Pharmacokinetic_Mechanism)[Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour](#Emerging_pharmacological_and_neuromodulation_interventions_for_suicidal_ideation_and_behaviour) - [Managing Interactions Without Therapeutic Compromise](#Managing_Interactions_Without_Therapeutic_Compromise)[Does cannabis or CBD interact with Blood Thinners & Anticoagulants?](#Does_cannabis_or_CBD_interact_with_Blood_Thinners_038_Anticoagulants) - [What monitoring or laboratory surveillance is required when taking cannabinoids alongside Blood Thinners & Anticoagulants?](#What_monitoring_or_laboratory_surveillance_is_required_when_taking_cannabinoids_alongside_Blood_Thinners_038_Anticoagulants) - [Related](#Related) # Cannabinoids & Blood Thinners & Anticoagulants: Evidence, Pharmacokinetics & Safety Review **Author & Reviewer:** [Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) • Family Medicine & Cannabinoid Specialist Clinical Bottom Line for Patients & Prescribers Cannabinoids interact with blood thinners & anticoagulants primarily through CYP2C9 and CYP3A4 competitive inhibition, which can reduce medication clearance and elevate international normalized ratio (INR), increasing bleeding risk. Unmonitored co-administration can alter therapeutic drug concentrations. Under physician guidance, adjustments to timing, route of administration, and objective laboratory surveillance allow patients to navigate therapy safely. ## 1. The Primary Pharmacokinetic Mechanism The human liver processes over 60% of all prescribed pharmaceuticals using the **Cytochrome P450 (CYP450) enzyme superfamily**. Cannabinoids-most notably cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC)-are both substrates and competitive inhibitors of specific CYP isoenzymes. Enzyme Pathway Dynamics **Mechanism:** CYP2C9 and CYP3A4 competitive inhibition, which can reduce medication clearance and elevate international normalized ratio (INR), increasing bleeding risk. **Medications Impacted:** Warfarin, Eliquis (apixaban), Xarelto (rivaroxaban). Featured Peer-Reviewed Investigation European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (2026) ### Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour **Lead Investigators:** Scala M, Magrini E, Leccisotti I, Serretti A, Gonda X et al. | **Identifier:** PMID: 42468074 **Study Findings & Abstract:** Suicide remains a leading cause of premature mortality worldwide. Current treatments are limited by delayed onset, durability, or poor tolerability. This narrative review, informed by a structured literature search, summarises the last decade of evidence on pharmacological and neuromodulation interventions for suicidal ideation (SI) or suicide attempt (SA) that are not approved for these indications. We searched PubMed for studies enrolling adults with SI or SA, including controlled trials and naturalistic/observational studies. Thirty-four studies were included: 22 pharmacological (13 efficacy, nine effectiveness) and 12 using neuromodulation (nine efficacy, three effectiveness). Across controlled trials, SI commonly improved within days to weeks. Some trials reported SI reduction beyond concurrent depression score changes, suggesting partial independence, but evidence remains inconsistent and method-dependent. Encouraging results were reported for NMDA-related drugs (NRX-101 and high-dose d-cycloserine; amantadine in Borna disease virus-1-positive depression), opioid-system modulation (buprenorphine at ultra-low and high doses in distinct populations), ayahuasca in major and treatment-resistant depression, and adjunctive pimavanserin. Smaller effects were observed for vortioxetine augmentation and insomnia-targeted zolpidem. Large observational datasets reported associations between lower suicidality and folic acid, benztropine, testosterone initiation in transgender adults, and non-vitamin K oral anticoagulants versus warfarin, whereas non-medical cannabis use was associated with worse SI trajectories. Neuromodulation evidence implicated accelerated or targeted repetitive transcranial magnetic stimulation, theta-burst stimulation, and magnetic seizure therapy for SI reduction, with longer-term observational support for vagus nerve stimulation. Future trials should prespecify suicide-related outcomes, test independence from mood change, and assess durability and high-risk transition periods to advance suicide-specific treatment development. [Access PubMed / DOI Reference Record →](https://doi.org/10.1016/j.euroneuro.2026.112888) Dr. Benjamin Caplan’s Clinical Perspective & Titration Protocol ### Managing Interactions Without Therapeutic Compromise *“Too often in clinical consultations, patients are given alarmist, blanket statements that they can ‘never use cannabis’ alongside prescription medication. In truth, pharmacology is a science of doses, affinities, and kinetics. When co-managing patients on blood thinners & anticoagulants, the goal is never to guess. We separate oral ingestion schedules by 2 to 3 hours, start with micro-titrated doses, and establish mandatory objective laboratory checkpoints to verify stability.”* **Mandatory Clinical Monitoring:** Frequent INR monitoring (for Warfarin) and clinical surveillance for spontaneous bruising, epistaxis, or hematuria. **Clinical Authority Context:** Dr. Benjamin Caplan, MD has overseen more than 350,000 patient evaluations across his career. He founded CED Clinic and curates the 125,000+ study CED Command Center literature observatory. Frequently Asked Clinical Questions • Direct Answers #### Does cannabis or CBD interact with Blood Thinners & Anticoagulants? Cannabinoids interact with blood thinners & anticoagulants primarily through CYP2C9 and CYP3A4 competitive inhibition, which can reduce medication clearance and elevate international normalized ratio (INR), increasing bleeding risk. Dosing should be systematically coordinated under physician co-management. #### What monitoring or laboratory surveillance is required when taking cannabinoids alongside Blood Thinners & Anticoagulants? Frequent INR monitoring (for Warfarin) and clinical surveillance for spontaneous bruising, epistaxis, or hematuria. Pharmacovigilance & Clinical Surveillance Audit Active Surveillance: Bi-Annual Review **Original Clinical Review:** October 2026 **Last Pharmacovigilance Audit:** Current (October 2026) **Auditing Clinician:** Benjamin Caplan, MD (ABFM) **Next Scheduled Review:** April 2027 Clinical pharmacokinetic guidance and cytochrome P450 interaction data are audited every 6 months against the CED Command Center computational literature vault and updated FDA prescribing inserts. Academic & Clinical Citation Format (AMA) Oxford CEBM Evidence Level 1A/2A Caplan B. Cannabinoids & Blood Thinners & Anticoagulants: Evidence, Pharmacokinetics & Safety Review. *CED Clinic Medication Safety & Pharmacology Series*. Published November 2026. https://cedclinic.com/cannabinoid-interactions-blood-thinners-anticoagulants-evidence/ [View Dr. Caplan’s Research & Bio →](https://cedclinic.com/drcaplan/) [Collaborative Physician Referral Portal →](https://cedclinic.com/physician-referral/) [Complex Medication Advisory →](https://cedclinic.com/advisor/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).